In stock COA-30%
NOVALYTE
LABS
LABS
NOVALYTELABS
CagriSema10mg · RESEARCH USE ONLY
CagriSema10mg · RESEARCH USE ONLY
In stock COA DOCUMENT SLOT-30%
Metabolic ResearchCagriSema
Combination research compound (Semaglutide + Cagrilintide) — dual GLP-1/amylin pathway agonist studied for synergistic metabolic effects.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundCagriSema
Presentation10mg injection pen
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
CagriSema is a combination research compound pairing semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analog) in a single preparation. Developed by Novo Nordisk, it exploits the complementary mechanisms of two distinct satiety hormone pathways. Phase 3 clinical data demonstrated approximately 20% average weight loss — significantly greater than either component alone — making it one of the most effective metabolic research combinations studied to date. The combination reflects a broader trend in metabolic research toward multi-receptor engagement.
Mechanism of Action
CagriSema engages two distinct anorexigenic pathways simultaneously. Semaglutide activates GLP-1 receptors on hypothalamic neurons (POMC/CART activation, NPY/AgRP inhibition), delays gastric emptying, and enhances glucose-dependent insulin secretion. Cagrilintide activates amylin receptors (AMY1-3) in the area postrema and hypothalamus — distinct neuronal populations that include histaminergic and dopaminergic circuits not reached by GLP-1 signalling. The non-overlapping central pathways produce additive appetite suppression, while both components independently delay gastric emptying and modulate glucagon release.
Research Applications
- Multi-receptor metabolic pathway synergy research
- GLP-1 and amylin receptor crosstalk studies
- Combination compound pharmacokinetics investigation
- Appetite regulation through complementary neuronal circuits
- Comparative efficacy studies vs mono-agonist approaches